The role of Hepatocyte Growth Factor (HGF) in insulin resistance and diabetes

Frontiers in Endocrinology

Volumn 9, Issue AUG, 2018, Pages

  Oliveira, Alexandre G ^a,b   Araújo, Tiago G ^a,c   Carvalho, Bruno de Melo ^a,d   Rocha, Guilherme Z ^a   Santos, Andrey ^a   Saad, Mario J A ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^d FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Beta cells; Diabetes; Hepatocyte growth factor; HGF; Inflammation; Insulin resistance; Obesity

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOTENSIN II; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 4; GLUCOSE TRANSPORTER 5; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; MAGNESIUM; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; SCATTER FACTOR;

ADIPOCYTE; CELL PROLIFERATION; DIABETES MELLITUS; DOWN REGULATION; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INFLAMMATION; INSULIN RESISTANCE; MOLECULAR BIOLOGY; NEOPLASM; NONHUMAN; OBESITY; PREGNANCY DIABETES MELLITUS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 85052834782     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2018.00503     Document Type: Review

References (119)

1. WHO. Obesity and Overweight (2012), p. 311. Available online at: http://www.who.int/mediacentre/factsheets/fs311/en/
2. Sieck G. Physiology in perspective: the burden of obesity. Physiology (Bethesda) (2014) 29:86-7. doi: 10.1152/physiol.00004.2014
3. Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. Lancet Diabet. Endocrinol. (2015) 3:207-15. doi: 10.1016/S2213-8587(14)70134-2
4. Saad MJ, Araki E, Miralpeix M, Rothenberg PL, White MF, Kahn CR. Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance. J Clin Invest. (1992) 90:1839-49. doi: 10.1172/JCI116060
5. Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest. (2000) 106:165-9. doi: 10.1172/JCI10582
6. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Ann Rev Immunol. (2011) 29:415-45. doi: 10.1146/annurev-immunol-031210-101322
7. Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab. (2009) 296:E581-91. doi: 10.1152/ajpendo.90437.2008
8. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. (2011) 11:98-107. doi: 10.1038/nri2925
9. Solinas G, Karin M. JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction. FASEB J. (2010) 24:2596-611. doi: 10.1096/fj.09-151340
10. Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. Pharm Econ. (2015) 33:811-31. doi: 10.1007/s40273-015-0268-9
11. Economic costs of diabetes in the U.S. in 2012. Diabetes Care (2013) 36:1033-46. doi: 10.2337/dc12-2625
12. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature (2006) 444, 840-6. doi: 10.1038/nature05482
13. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. (2006) 116:1793-801. doi: 10.1172/JCI29069
14. Stefan N, Haring HU. The role of hepatokines in metabolism. Nat Rev Endocrinol. (2013) 9:144-52. doi: 10.1038/nrendo.2012.258
15. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science (2011) 332:1519-23. doi: 10.1126/science.1204265
16. Nordlie RC, Foster JD, Lange AJ. Regulation of glucose production by the liver. Ann Rev Nutr. (1999) 19:379-406. doi: 10.1146/annurev.nutr.19.1.379
17. Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat. Rev. Endocrinol. (2017) 13:509-20. doi: 10.1038/nrendo.2017.56
18. Li Q, Zhang Y, Ding D, Yang Y, Chen Q, Su D, et al. Association between serum fibroblast growth factor 21 and mortality among patients with coronary artery disease. J Clin Endocrinol Metab. (2016) 101:4886-94. doi: 10.1210/jc.2016-2308
19. Tsukagawa E, Adachi H, Hirai Y, Enomoto M, Fukami A, Ogata K, et al. Independent association of elevated serum hepatocyte growth factor levels with development of insulin resistance in a 10-year prospective study. Clin Endocrinol. (Oxf.) (2013) 79:43-8. doi: 10.1111/j.1365-2265.2012.04496.x
20. Rahimi N, Saulnier R, Nakamura T, Park M, Elliott B. Role of hepatocyte growth factor in breast cancer: a novel mitogenic factor secreted by adipocytes. DNA Cell Biol. (1994) 13:1189-97
21. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology (2004) 145:2273-82. doi: 10.1210/en.2003-1336
22. Bell LN, Ward JL, Degawa-Yamauchi M, Bovenkerk JE, Jones R, Cacucci BM, et al. Adipose tissue production of hepatocyte growth factor contributes to elevated serum HGF in obesity. Am J Physiol Endocrinol Metab. (2006) 291:E843-8. doi: 10.1152/ajpendo.00174.2006
23. Hiratsuka A, Adachi H, Fujiura Y, Yamagishi S, Hirai Y, Enomoto M, et al. Strong association between serum hepatocyte growth factor and metabolic syndrome. J Clin Endocrinol Metab. (2005) 90:2927-31. doi: 10.1210/jc.2004-1588
24. Vistoropsky Y, Trofimov S, Malkin I, Kobyliansky E, Livshits G. Genetic and environmental determinants of hepatocyte growth factor levels and their association with obesity and blood pressure. Ann Hum Biol. (2008) 35:93-103. doi: 10.1080/03014460701822003
25. Bertola A, Bonnafous S, Cormont M, Anty R, Tanti JF, Tran A, et al. Hepatocyte growth factor induces glucose uptake in 3T3-L1 adipocytes through A Gab1/phosphatidylinositol 3-kinase/Glut4 pathway. J Biol Chem. (2007) 282:10325-32. doi: 10.1074/jbc.M611770200
26. Rittig K, Dolderer JH, Balletshofer B, Machann J, Schick F, Meile T, et al. The secretion pattern of perivascular fat cells is different from that of subcutaneous and visceral fat cells. Diabetologia (2012) 55:1514-25. doi: 10.1007/s00125-012-2481-9
27. Rehman J, Considine RV, Bovenkerk JE, Li J, Slavens CA, Jones RM, et al. Obesity is associated with increased levels of circulating hepatocyte growth factor. J Am Coll Cardiol. (2003) 41:1408-13. doi: 10.1016/S0735-1097(03)00231-6
28. Swierczynski J, Korczynska J, Goyke E, Adrych K, Raczynska S, Sledzinski Z. Serum hepatocyte growth factor concentration in obese women decreases after vertical banded gastroplasty. Obes Surg. (2005) 15:803-8. doi: 10.1381/0960892054222678
29. Amato MC, Pizzolanti G, Torregrossa V, Misiano G, Milano S, Giordano C. Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes. PLoS ONE (2014) 9:e91969. doi: 10.1371/journal.pone.0091969
30. de Courten B, de Courten MP, Dougherty S, Forbes JM, Potts JR, Considine RV. Insulin infusion reduces hepatocyte growth factor in lean humans. Metabolism (2013) 62:647-50. doi: 10.1016/j.metabol.2012.10.013
31. Fafalios A, Ma J, Tan X, Stoops J, Luo J, Defrances MC, et al. A hepatocyte growth factor receptor (Met)-insulin receptor hybrid governs hepatic glucose metabolism. Nat Med. (2011) 17:1577-84. doi: 10.1038/nm.2531
32. Garcia-Ocana A, Vasavada RC, Cebrian A, Reddy V, Takane KK, Lopez-Talavera JC, et al. Transgenic overexpression of hepatocyte growth factor in the β-cell markedly improves islet function and islet transplant outcomes in mice. Diabetes (2001) 50:2752-62. doi: 10.2337/diabetes.50.12.2752
33. Roccisana J, Reddy V, Vasavada RC, Gonzalez-Pertusa JA, Magnuson MA, Garcia-Ocana A. Targeted inactivation of hepatocyte growth factor receptor c-met in beta-cells leads to defective insulin secretion and GLUT-2 downregulation without alteration of β-cell mass. Diabetes (2005) 54:2090-102. doi: 10.2337/diabetes.54.7.2090
34. Kato Y, Yu D, Schwartz MZ. Hepatocyte growth factor up-regulates SGLT1 and GLUT5 gene expression after massive small bowel resection. J Pediatr Surg. (1998) 33:13-5
35. Perdomo G, Martinez-Brocca MA, Bhatt BA, Brown NF, O'Doherty RM, Garcia-Ocana A. Hepatocyte growth factor is a novel stimulator of glucose uptake and metabolism in skeletal muscle cells. J Biol Chem. (2008) 283:13700-6. doi: 10.1074/jbc.M707551200
36. Sanchez-Encinales V, Cozar-Castellano I, Garcia-Ocana A, Perdomo G. Targeted delivery of HGF to the skeletal muscle improves glucose homeostasis in diet-induced obese mice. J Physiol Biochem. (2015) 71:795-805. doi: 10.1007/s13105-015-0444-6
37. Araujo TG, Oliveira AG, Carvalho BM, Guadagnini D, Protzek AO, Carvalheira JB, et al. Hepatocyte growth factor plays a key role in insulin resistance-associated compensatory mechanisms. Endocrinology (2012) 153:5760-9. doi: 10.1210/en.2012-1496
38. Demirci C, Ernst S, Alvarez-Perez JC, Rosa T, Valle S, Shridhar V, et al. Loss of HGF/c-Met signaling in pancreatic beta-cells leads to incomplete maternal beta-cell adaptation and gestational diabetes mellitus. Diabetes (2012) 61:1143-52. doi: 10.2337/db11-1154
39. Araujo TG, Oliveira AG, Saad MJ. Insulin-resistance-associated compensatory mechanisms of pancreatic Beta cells: a current opinion. Front Endocrinol. (2013) 4:146. doi: 10.3389/fendo.2013.00146
40. Otonkoski T, Beattie GM, Rubin JS, Lopez AD, Baird A, Hayek A. Hepatocyte growth factor/scatter factor has insulinotropic activity in human fetal pancreatic cells. Diabetes (1994) 43:947-53
41. Otonkoski T, Cirulli V, Beattie M, Mally MI, Soto G, Rubin JS, et al. A role for hepatocyte growth factor/scatter factor in fetal mesenchyme-induced pancreatic beta-cell growth. Endocrinology (1996) 137:3131-9
42. Hayek A, Beattie GM, Cirulli V, Lopez AD, Ricordi C, Rubin JS. Growth factor/matrix-induced proliferation of human adult beta-cells. Diabetes (1995) 44:1458-60
43. Dai C, Huh CG, Thorgeirsson SS, Liu Y. Beta-cell-specific ablation of the hepatocyte growth factor receptor results in reduced islet size, impaired insulin secretion, and glucose intolerance. Am J Pathol. (2005) 167:429-36. doi: 10.1016/S0002-9440(10)62987-2
44. Alvarez-Perez JC, Rosa TC, Casinelli GP, Valle SR, Lakshmipathi J, Rosselot C, et al. Hepatocyte growth factor ameliorates hyperglycemia and corrects beta-cell mass in IRS2-deficient mice. Mol Endocrinol. (2014) 28:2038-48. doi: 10.1210/me.2014-1207
45. Alvarez-Perez JC, Ernst S, Demirci C, Casinelli GP, Mellado-Gil JM, Rausell-Palamos F, et al. Hepatocyte growth factor/c-Met signaling is required for beta-cell regeneration. Diabetes (2014) 63:216-23. doi: 10.2337/db13-0333
46. Mellado-Gil J, Rosa TC, Demirci C, Gonzalez-Pertusa JA, Velazquez-Garcia S, Ernst S, et al. Disruption of hepatocyte growth factor/c-Met signaling enhances pancreatic beta-cell death and accelerates the onset of diabetes. Diabetes (2011) 60:525-36. doi: 10.2337/db09-1305
47. Garcia-Ocana A, Takane KK, Syed MA, Philbrick WM, Vasavada RC, Stewart AF. Hepatocyte growth factor overexpression in the islet of transgenic mice increases beta cell proliferation, enhances islet mass, and induces mild hypoglycemia. J Biol Chem. (2000) 275:1226-32. doi: 10.1074/jbc.275.2.1226
48. Coudriet GM, He J, Trucco M, Mars WM, Piganelli JD. Hepatocyte growth factor modulates interleukin-6 production in bone marrow derived macrophages: implications for inflammatory mediated diseases. PLoS ONE (2010) 5:e15384. doi: 10.1371/journal.pone.0015384
49. Flaquer M, Franquesa M, Vidal A, Bolanos N, Torras J, Lloberas N, et al. Hepatocyte growth factor gene therapy enhances infiltration of macrophages and may induce kidney repair in db/db mice as a model of diabetes. Diabetologia (2012). doi: 10.1007/s00125-012-2535-z
50. Shimizu K, Taniyama Y, Sanada F, Azuma J, Iwabayashi M, Iekushi K, et al. Hepatocyte growth factor inhibits lipopolysaccharide-induced oxidative stress via epithelial growth factor receptor degradation. Arterioscler Thromb Vasc Biol. (2012) 32:2687-93. doi: 10.1161/ATVBAHA.112.300041
51. Kusunoki H, Taniyama Y, Otsu R, Rakugi H, Morishita R. Anti-inflammatory effects of hepatocyte growth factor on the vicious cycle of macrophages and adipocytes. Hypertens Res. (2014) 37:500-6. doi: 10.1038/hr.2014.41
52. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature (1989) 342:440-3. doi: 10.1038/342440a0
53. Nakamura T, Sakai K, Matsumoto K. Hepatocyte growth factor twenty years on: Much more than a growth factor. J Gastroenterol Hepatol. (2011) 26(Suppl. 1):188-202. doi: 10.1111/j.1440-1746.2010.06549.x
54. Fiaschi-Taesch NM, Berman DM, Sicari BM, Takane KK, Garcia-Ocana A, Ricordi C, et al. Hepatocyte growth factor (HGF) enhances engraftment and function of non-human primate islets. Diabetes (2008) 57: 2745-54. doi: 10.2337/db07-1085
55. Seki T, Hagiya M, Shimonishi M, Nakamura T, Shimizu S. Organization of the human hepatocyte growth factor-encoding gene. Gene (1991) 102:213-9
56. Stella MC, Comoglio PM. HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol. (1999) 31:1357-62
57. Naka D, Ishii T, Yoshiyama Y, Miyazawa K, Hara H, Hishida T, et al. Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer. J Biol Chem. (1992) 267:20114-9
58. Miyazawa K, Shimomura T, Naka D, Kitamura N. Proteolytic activation of hepatocyte growth factor in response to tissue injury. J Biol Chem. (1994) 269:8966-70
59. Shimomura T, Miyazawa K, Komiyama Y, Hiraoka H, Naka D, Morimoto Y, et al. Activation of hepatocyte growth factor by two homologous proteases, blood-coagulation factor XIIa and hepatocyte growth factor activator. Eur J Biochem. (1995) 229:257-61
60. Itoh H, Hamasuna R, Kataoka H, Yamauchi M, Miyazawa K, Kitamura N, et al. Mouse hepatocyte growth factor activator gene: its expression not only in the liver but also in the gastrointestinal tract. Biochim Biophys Acta (2000) 1491:295-302. doi: 10.1016/S0167-4781(00)00029-4
61. Yanagida H, Kaibori M, Hijikawa T, Kwon AH, Kamiyama Y, Okumura T. Administration of rhHGF-activator via portal vein stimulates the regeneration of cirrhotic liver after partial hepatectomy in rats. J Surg Res. (2006) 130:38-44. doi: 10.1016/j.jss.2005.08.002
62. Shimomura T, Kondo J, Ochiai M, Naka D, Miyazawa K, Morimoto Y, et al. Activation of the zymogen of hepatocyte growth factor activator by thrombin. J Biol Chem. (1993) 268:22927-32
63. Hayashi T, Nishioka J, Nakagawa N, Kamada H, Gabazza EC, Kobayashi T, et al. Protein C inhibitor directly and potently inhibits activated hepatocyte growth factor activator. J Thromb Haemost. (2007) 5:1477-85. doi: 10.1111/j.1538-7836.2007.02594.x
64. Hartmann G, Naldini L, Weidner KM, Sachs M, Vigna E, Comoglio PM, et al. A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. Proc Natl Acad Sci USA (1992) 89:11574-8
65. De Meyts P. Insulin and its receptor: structure, function and evolution. Bioessays (2004) 26:1351-62. doi: 10.1002/bies.20151
66. Rosario M, Birchmeier W. How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol. (2003) 13:328-35. doi: 10.1016/S0962-8924(03)00104-1
67. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature (1998) 391:900-4
68. Kushner JA, Ye J, Schubert M, Burks DJ, Dow MA, Flint CL, et al. Pdx1 restores beta cell function in Irs2 knockout mice. J Clin Invest. (2002) 109:1193-201. doi: 10.1172/JCI14439
69. Ernst S, Demirci C, Valle S, Velazquez-Garcia S, Garcia-Ocana A. Mechanisms in the adaptation of maternal beta-cells during pregnancy. Diabetes Manag. (Lond.). (2011) 1:239-48. doi: 10.2217/dmt.10.24
70. Johansson M, Mattsson G, Andersson A, Jansson L, Carlsson PO. Islet endothelial cells and pancreatic beta-cell proliferation: studies in vitro and during pregnancy in adult rats. Endocrinology (2006) 147:2315-24. doi: 10.1210/en.2005-0997
71. Selig PM. Metabolic syndrome in the acute care setting. AACN Clin Issues (2006) 17:79-85
72. Shiota G, Umeki K, Okano J, Kawasaki H. Hepatocyte growth factor and acute phase proteins in patients with chronic liver diseases. J Med. (1995) 26:295-308
73. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (2003) 37:917-23. doi: 10.1053/jhep.2003.50161
74. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc. (2001) 60:329-39
75. Rajpathak SN, Wassertheil-Smoller S, Crandall J, Liu S, Ho GY. Hepatocyte growth factor and clinical diabetes in postmenopausal women. Diabetes Care (2010) 33:2013-5. doi: 10.2337/dc10-0710
76. Bancks MP, Bielinski SJ, Decker PA, Hanson NQ, Larson NB, Sicotte H, et al. Circulating level of hepatocyte growth factor predicts incidence of type 2 diabetes mellitus: the Multi-Ethnic Study of Atherosclerosis (MESA). Metabolism (2016) 65:64-72. doi: 10.1016/j.metabol.2015.10.023
77. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. (2005) 115:1111-9. doi: 10.1172/JCI25102
78. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. (2003) 112:1821-30. doi: 10.1172/JCI19451
79. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. (2000) 106:473-81. doi: 10.1172/JCI10842
80. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care (2004) 27:813-23. doi: 10.2337/diacare.27.3.813
81. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. (2006) 116:1494-505. doi: 10.1172/JCI26498
82. Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem. (2006) 281:26602-14. doi: 10.1074/jbc.M601284200
83. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, Vats D, Morel CR, Goforth MH, et al. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab (2008) 7:496-507. doi: 10.1016/j.cmet.2008.04.003
84. Muratsu J, Iwabayashi M, Sanada F, Taniyama Y, Otsu R, Rakugi H, et al. Hepatocyte growth factor prevented high-fat diet-induced obesity and improved insulin resistance in mice. Sci Rep. (2017) 7:130. doi: 10.1038/s41598-017-00199-4
85. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. (2003) 348:1625-38. doi: 10.1056/NEJMoa021423
86. Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Ann Rev Med. (2010) 61:301-16. doi: 10.1146/annurev.med.080708.082713
87. Osorio-Costa F, Rocha GZ, Dias MM, Carvalheira JB. Epidemiological and molecular mechanisms aspects linking obesity and cancer. Arq Bras Endocrinol Metabol. (2009) 53:213-26. doi: 10.1590/S0004-27302009000200013
88. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer (2009) 9:239-52. doi: 10.1038/nrc2618
89. Cirri P, Chiarugi P. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metast Rev. (2012) 31:195-208. doi: 10.1007/s10555-011-9340-x
90. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. (1986) 315:1650-9. doi: 10.1056/NEJM198612253152606
91. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer (2016) 16:582-98. doi: 10.1038/nrc.2016.73
92. Weidner KM, Arakaki N, Hartmann G, Vandekerckhove J, Weingart S, Rieder H, et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci USA (1991) 88:7001-5
93. Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. (1991) 10:2867-78
94. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature (1987) 327:239-42. doi: 10.1038/327239a0
95. Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Therap Adv Med Oncol. (2011) 3(1 Suppl):S21-35. doi: 10.1177/1758834011422557
96. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. (2008) 7:504-16. doi: 10.1038/nrd2530
97. Seneviratne D, Ma J, Tan X, Kwon YK, Muhammad E, Melhem M, et al. Genomic instability causes HGF gene activation in colon cancer cells, promoting their resistance to necroptosis. Gastroenterology (2015) 148:181-91 e17. doi: 10.1053/j.gastro.2014.09.019
98. Fukuura T, Miki C, Inoue T, Matsumoto K, Suzuki H. Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma. Br J Cancer (1998) 78:454-9
99. Toiyama Y, Miki C, Inoue Y, Okugawa Y, Tanaka K, Kusunoki M. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. Int J Cancer (2009) 125:1657-62. doi: 10.1002/ijc.24554
100. Toi M, Taniguchi T, Ueno T, Asano M, Funata N, Sekiguchi K, et al. Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin Cancer Res. (1998) 4:659-64
101. Taniguchi T, Toi M, Inada K, Imazawa T, Yamamoto Y, Tominaga T. Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res. (1995) 1:1031-4
102. Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood (1998) 91:806-12
103. Verstovsek S, Kantarjian H, Estey E, Aguayo A, Giles FJ, Manshouri T, et al. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia (2001) 15:1165-70
104. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 487:500-4. doi: 10.1038/nature11183
105. Owusu BY, Bansal N, Venukadasula PK, Ross LJ, Messick TE, Goel S, et al. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. Oncotarget (2016) 7:29492-506. doi: 10.18632/oncotarget.8785
106. Pallangyo CK, Ziegler PK, Greten FR. IKKbeta acts as a tumor suppressor in cancer-associated fibroblasts during intestinal tumorigenesis. J Exp Med. (2015) 212:2253-66. doi: 10.1084/jem.20150576
107. Luraghi P, Reato G, Cipriano E, Sassi F, Orzan F, Bigatto V, et al. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res. (2014) 74:1857-69. doi: 10.1158/0008-5472.CAN-13-2340-T
108. Jia CC, Wang TT, Liu W, Fu BS, Hua X, Wang GY, et al. Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion. PLoS ONE (2013) 8:e63243. doi: 10.1371/journal.pone.0063243
109. Smith BN, Bhowmick NA. Role of EMT in metastasis and therapy resistance. J Clin Med. (2016) 5:17. doi: 10.3390/jcm5020017
110. Huang J, Li H, Ren G. Epithelial-mesenchymal transition and drug resistance in breast cancer (Review). Int J Oncol. (2015) 47:840-8. doi: 10.3892/ijo.2015.3084
111. Owusu BY, Thomas S, Venukadasula P, Han Z, Janetka JW, Galemmo RA Jr., et al. Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. Oncotarget (2017) 8:63014-25. doi: 10.18632/oncotarget.18260
112. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature (2013) 502:333-9. doi: 10.1038/nature12634
113. Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. (2010) 12:468-76. doi: 10.1038/ncb2048
114. De Bacco F, D'Ambrosio A, Casanova E, Orzan F, Neggia R, Albano R, et al. MET inhibition overcomes radiation resistance of glioblastoma stem-like cells. EMBO Mol Med. (2016) 8:550-68. doi: 10.15252/emmm.201505890
115. Boccaccio C, Comoglio PM. The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target. Cancer Res. (2013) 73:3193-9. doi: 10.1158/0008-5472.CAN-12-4039
116. Sun S, Liu S, Duan SZ, Zhang L, Zhou H, Hu Y, et al. Targeting the c-Met/FZD8 signaling axis eliminates patient-derived cancer stem-like cells in head and neck squamous carcinomas. Cancer Res. (2014) 74:7546-59. doi: 10.1158/0008-5472.CAN-14-0826
117. van Leenders GJ, Sookhlall R, Teubel WJ, de Ridder CM, Reneman S, Sacchetti A, et al. Activation of c-MET induces a stem-like phenotype in human prostate cancer. PLoS ONE (2011) 6:e26753. doi: 10.1371/journal.pone.0026753
118. Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH, et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology (2011) 141:2218-27 e5. doi: 10.1053/j.gastro.2011.08.009
119. Iroz A, Couty JP, Postic C. Hepatokines: unlocking the multi-organ network in metabolic diseases. Diabetologia (2015) 58:1699-703. doi: 10.1007/s00125-015-3634-4